

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 November 2024 (14.11.2024)



(10) International Publication Number
WO 2024/229569 A1

(51) International Patent Classification:

A61K 31/4439 (2006.01)	A61P 37/06 (2006.01)
A61K 31/444 (2006.01)	C07D 309/12 (2006.01)
A61K 31/496 (2006.01)	C07D 309/14 (2006.01)
A61K 31/506 (2006.01)	C07D 409/12 (2006.01)
A61K 31/519 (2006.01)	C07D 409/14 (2006.01)
A61K 31/4178 (2006.01)	C07D 413/14 (2006.01)
A61K 31/4436 (2006.01)	C07D 471/04 (2006.01)
A61K 31/4545 (2006.01)	C07D 487/04 (2006.01)
A61K 31/5377 (2006.01)	C07D 495/04 (2006.01)

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/CA2024/050624

(22) International Filing Date:

08 May 2024 (08.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/464,994 09 May 2023 (09.05.2023) US

(71) Applicant: **11949098 CANADA INC.** [CA/CA]; 7395 Malraux Place, BROSSARD, Québec J4Y 1S5 (CA).

(72) Inventors: **FOUDA, Ahmed**; 212-5615 avenue Emerald, Cote Saint Luc, Montreal, Québec H4W 2S7 (CA). **TCHERVENKOV, Jean**; 7395 Place Malraux, BROSSARD, Québec J4Y 1S5 (CA). **PARASKEVAS, Steven**; 3790 avenue de Vendôme, Montreal, Québec H4A 3M9 (CA). **NEGI, Sarita**; 5118 avenue Westmore, Montreal, Québec H4V 1Z5 (CA).

(74) Agent: **BENOIT ET CÔTÉ INC.**; 300-560 Crémazie Blvd. East, Montreal, Québec H2P 1E8 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: INVERSE AGONISTS OF RAR RELATED ORPHAN RECEPTORS (RORS)

(57) Abstract: The invention relates to the use of a ROR inverse agonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for modulating RORs and/or controlling autoimmune diseases and antibody mediated rejection in a patient. The RORs mediated disease or autoimmune disease includes HIV, cancer, celiac disease, diabetes mellitus type 1, Graves' disease, inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease, cardiovascular disease, inflammatory diseases, neurological disorder, multiple sclerosis, acute respiratory distress syndrome and arteriosclerosis.



WO 2024/229569 A1